Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jul. 31, 2018
Jul. 31, 2017
Jul. 31, 2016
Revenues:      
Revenues $ 104,713 $ 107,804 $ 102,773
Operating costs, expenses and legal settlements, net:      
Research and development 3,210 2,928 3,524
Selling, general, and administrative 44,465 44,092 43,741
Provision for uncollectible accounts receivable 3,690 2,775 2,336
Legal fee expense 5,127 1,679 6,384
Legal settlements, net     (57,250)
Total costs, expenses and legal settlements, net 116,877 110,952 55,925
Operating (loss) income (12,164) (3,148) 46,848
Other income (expense):      
Interest 853 384 (136)
Other 168 125 122
Foreign exchange gain (loss) (275) 135 (474)
(Loss) income before income taxes (11,418) (2,504) 46,360
(Provision) benefit for income taxes 1,097   (1,074)
Net (loss) income $ (10,321) $ (2,504) $ 45,286
Net (loss) income per common share:      
Basic (in Dollars per share) $ (0.22) $ (0.05) $ 0.98
Diluted (in Dollars per share) $ (0.22) $ (0.05) $ 0.97
Weighted average common shares outstanding:      
Basic (in Shares) 46,972 46,350 46,153
Diluted (in Shares) 46,972 46,350 46,602
Clinical Laboratory Services [Member]      
Revenues:      
Revenues $ 74,777 $ 77,407 $ 70,915
Operating costs, expenses and legal settlements, net:      
Cost of Revenues 46,008 45,400 42,859
Product [Member]      
Revenues:      
Revenues 29,224 29,192 30,337
Operating costs, expenses and legal settlements, net:      
Cost of Revenues 14,377 14,078 14,331
Royalty and License Fees [Member]      
Revenues:      
Revenues $ 712 $ 1,205 $ 1,521